<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388086</url>
  </required_header>
  <id_info>
    <org_study_id>2017-17</org_study_id>
    <nct_id>NCT03388086</nct_id>
  </id_info>
  <brief_title>Efficacy of Two Onabotulinum Toxin Doses</brief_title>
  <official_title>Comparing the Efficacy of Two Doses of Onabotulinum Toxin for the Treatment of Neurogenic Detrusor Overactivity - a Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The changes in bladder function after the injection of Onabotulinum toxin into the detrusor
      in individuals with neurogenic bladder overactivity will be investigated retrospectively. The
      records of all patients treated with Onabotulinum toxin injections into the detrusor since
      2000 will be evaluated. The changes in the urodynamic values after the injection of 300 units
      of Onabotulinum toxin will be compared with the changes after the injection of 200 units.
      Furthermore, the differences in urinary continence, duration between injections, side effects
      and complications between the two groups will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in detrusor pressure post-injection</measure>
    <time_frame>within 3 months before injection; within 2 months after injection</time_frame>
    <description>bladder detrusor pressure during storage phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum bladder volume</measure>
    <time_frame>within 3 months before injection; within 2 months after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bladder compliance</measure>
    <time_frame>within 3 months before injection; within 2 months after injection</time_frame>
    <description>The relationship between a change in bladder volume and the change in detrusor pressure (ΔDV/ΔDP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reflexive bladder volume</measure>
    <time_frame>within 3 months before injection; within 2 months after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>within 2 months after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of urinary incontinence</measure>
    <time_frame>within 3 months before injection; within 2 months after injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>lesion level</measure>
    <time_frame>at the time of spinal cord injury</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>lesion severity</measure>
    <time_frame>at the time of spinal cord injury</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>method of bladder evacuation</measure>
    <time_frame>within 2 months after injection</time_frame>
    <description>evacuation by intermittent catheterization, reflex voiding, suprapubic catheter , electric stimulation</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Neurogenic Bladder</condition>
  <condition>Overactive Detrusor</condition>
  <arm_group>
    <arm_group_label>Onabotulinum 300 units</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Onabotulinum 200 units</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of Onabotulinum toxin</intervention_name>
    <description>multiple injections of Onabotulinum toxin into the detrusor muscle</description>
    <arm_group_label>Onabotulinum 200 units</arm_group_label>
    <arm_group_label>Onabotulinum 300 units</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated with Onabotulinum toxin for neurogenic detrusor overactivity as a result
        of spinal cord injury
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neurogenic detrusor overactivity

          -  spinal cord injury

          -  Onabotulinum toxin injections into the detrusor from 2000-2017

        Exclusion Criteria:

          -  missing urodynamic values before or after Onabotulinum toxin injections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre</name>
      <address>
        <city>Nottwil</city>
        <state>LU</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

